31/03/2026 Galapagos and Gilead entered into a binding agreement to collaborate on advancing a T cell engager program for autoimmune diseases Galapagos and Gilead entered into a binding agreement to collaborate on advancing a T cell engager program for autoimmune diseases ( Ref ) Galapagos and Gilead Sciences entered into a binding collaboration agreement to co-develop gamgertamig (OM336; BCMAxCD3 T cell engager) originally developed by Ouro Medicines targeting deep B-cell de